# Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)

> **NCT02947620** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 185 (actual)

## Conditions studied

- Type II Diabetes
- Dyslipidemia

## Interventions

- **DRUG:** Metformin/Atorvastatin 1500mg/40mg, QD
- **DRUG:** Metformin 1500mg, QD
- **DRUG:** Atorvastatin 40mg, QD

## Key facts

- **NCT ID:** NCT02947620
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2017-02-27
- **Final completion:** 2017-02-27
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947620, "Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02947620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*